The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC

被引：3
|
作者：
Elamin, Y. [1 ]
Robichaux, J. [1 ]
Lam, V. [2 ]
Tsao, A. [3 ]
Lu, C. [1 ]
Blumenschein, G. [4 ]
Kurie, J. [1 ]
Brahmer, J. [5 ]
Li, S.
Chen, T. [7 ]
Estrada-Bernal, A. [8 ]
Truini, A. [9 ]
Nilsson, M. [1 ]
Le, A.
Tan, Z. [1 ]
Zhang, S. [1 ]
Doebele, R. [10 ]
Politi, K. [9 ,12 ]
Yang, Z. [11 ]
Liu, S. [6 ]
Wong, K.
Heymach, J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Thorac & Head & Neck Med Oncol, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Dana Farber Canc Inst, Med Oncol, Boston, MA 02115 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] Univ Colorado Amc, Med Oncol, Aurora, CO USA
[9] Yale Univ, Pathol, New Haven, CT USA
[10] Univ Colorado, Div Med Oncol, Aurora, CO USA
[11] Spectrum Pharmaceut, Irvine, CA USA
[12] NYU, Langone Med Ctr, Div Hematol Oncol, New York, NY USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
EGFR Exon 20 Insertion mutation; Novel targeted therapy;
D O I：
10.1016/j.jtho.2017.09.394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA 12.01
引用
收藏
页码：S1776 / S1776
页数：1
相关论文
共 50 条
  • [31] Preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions
    Nagamoto, Y.
    Miyamoto, M.
    Togashi, N.
    Taira, T.
    Jimbo, T.
    Isoyama, T.
    Takahashi, M.
    Takeuchi, K.
    Yoshida, K-I.
    Higuchi, S.
    Seki, T.
    Abe, Y.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S248 - S248
  • [32] Discovery of selective and potent EGFR kinase inhibitors for exon20 insertion mutations
    Kim, Sunghwan
    Lee, Younho
    Kim, Hwan
    Kang, Juhee
    Seok, Jiyoon
    Seo, Kyung-Ah
    Ahn, Jaeyoung
    Kang, Hee-Bum
    Lee, Sun-Hwa
    Son, Jung Beom
    Choi, Hwan Geun
    Kim, Nam Doo
    [J]. MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [33] A comprehensive overview of the heterogeneity of EGFR exon 20 variants in NSCLC and (pre)clinical activity to currently available treatments
    Zwierenga, Fenneke
    van Veggel, Bianca A. M. H.
    Van den Berg, Anke
    Groen, Harry J. M.
    Zhang, Lili
    Groves, Matthew R.
    Kok, K.
    Smit, E. F.
    Hiltermann, T. Jeroen N.
    de Langen, Adrianus J.
    Van der Wekken, Anthonie J.
    [J]. CANCER TREATMENT REVIEWS, 2023, 120
  • [34] Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC)
    Janne, Pasi A.
    Ramalingam, Suresh S.
    Yang, James Chih-Hsin
    Ahn, Myung-Ju
    Kim, Dong-Wan
    Kim, Sang-We
    Planchard, David
    Ohe, Yuichiro
    Felip, Enriqueta
    Watkins, Claire
    Cantarini, Mireiille
    Ghiorghiu, Serban
    Ranson, Malcolm
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] Preclinical Activity of AZD9291 in EGFR-Mutant NSCLC Brain Metastases
    Ballard, Peter
    Yang, Pamela
    Cross, Darren
    Yates, James
    Finlay, M. Raymond V.
    Grist, Matthew
    Box, Matthew
    Johnstrom, Peter
    Varnas, Katerina
    Malmquist, Jonas
    Halldin, Christer
    Farde, Lars
    Thress, Kenneth
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S300 - S300
  • [36] A Phase 1b Study Of Furmonertinib, an Oral, Brain Penetrant, Selective EGFR Inhibitor, in Patients with Advanced NSCLC with EGFR Exon 20 Insertions
    Han, B.
    Zhou, C.
    Zheng, W.
    Wu, L.
    Ma, Z.
    Wang, H.
    Yu, X.
    Ding, G.
    Ma, D.
    Nie, L.
    Zhang, Z.
    Dong, X.
    Shang, Y.
    Tang, K.
    Zhang, W.
    Hsu, J. Y.
    Jiang, Y.
    Zhao, Q.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S49 - S49
  • [37] Preclinical pharmacokinetic and pharmacological properties of ASP8273, a mutant-selective irreversible EGFR inhibitor, and its potential activity against brain metastases in NSCLC
    Fushiki, H.
    Kaneko, N.
    Yamanaka, Y.
    Fujita, Y.
    Noda, A.
    Umeda, N.
    Sakagami, H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 69 : S41 - S41
  • [38] Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC
    Dorkhom, N. V.
    Cannon, M.
    Cohen, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S645 - S645
  • [39] Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.
    Piotrowska, Zofia
    Costa, Daniel Botelho
    Huberman, Mark
    Oxnard, Geoffrey R.
    Gainor, Justin F.
    Heist, Rebecca Suk
    Muzikansky, Alona
    Shaw, Alice Tsang
    Niederst, Matthew J.
    Fulton, Linnea
    Engelman, Jeffrey A.
    Sequist, Lecia V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Antitumor activity of TAK-788 in NSCLC with EGFR exon 20 insertions.
    Janne, Pasi A.
    Neal, Joel W.
    Camidge, D. Ross
    Spira, Alexander I.
    Piotrowska, Zofia
    Horn, Leora
    Costa, Daniel Botelho
    Tsao, Anne S.
    Patel, Jyoti D.
    Gadgeel, Shirish M.
    Bazhenova, Lyudmila
    Zhu, Viola Weijia
    West, Howard
    Vincent, Sylvie
    Zhu, Jian
    Li, Shuanglian
    Riely, Gregory J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345